A Phase 2 interventional study of Crinecerfont in Congenital Adrenal Hyperplasia, sponsored by Neurocrine Switzerland GmbH. Recruiting at 11 sites in United States. Open to participants aged 3 Months to 47 Months. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Neurocrine Switzerland GmbH (part of Neurocrine Biosciences) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences — 2 open to participants now, 5 under way, 2 of them phase 3. Adrenal Hyperplasia, Congenital · Neurocrine Biosciences.
Among the 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences, this one is the 9th largest by planned enrollment, is one of 2 that started in 2026, is one of 6 in phase 2, and was the 15th registered.
101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.
Browse Adrenal Hyperplasia, Congenital studies →2 of the 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences are open now, in 1 country. Recruiting first, the newest first:
Neurocrine Biosciences
Ages 18–65
By country, each count listing its studies:
Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.
This study: 3 Months to 47 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 6
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 37 across 50 interventional studies indexed under Adrenal Hyperplasia, Congenital.
Median enrollment 24 across the 16 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Neurocrine Switzerland GmbH, one of the names counted as Neurocrine Biosciences. Under that name alone:
Neurocrine Switzerland GmbH is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with CAH will receive crinecerfont.
Drug: Crinecerfont
Oral solution
Number of Participants With Treatment-emergent Adverse Events (TEAE)
Time frame: Day 1 up to 28 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Mar 2028, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crinecerfont
Adrenal Hyperplasia, Congenital →